Dapagliflozin · Farxiga / Forxiga

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Heart Failure, Chronic Kidney Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Atherosclerotic Cardiovascular Disease · Phase 3 · investigational in the US

Also approved (2)
JP
  • Type 2 diabetes mellitus (Forxiga 5 mg, 10 mg tablets)
Product first approved 2014ono-pharma.com
EU
  • Type 2 diabetes (Forxiga; later extended to chronic heart failure and chronic kidney disease)
Product first approved 2012EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (122)
Atherosclerotic Cardiovascular Disease
NCT06772168 · CMG Pharmaceutical Co. Ltd
2024-04-19 – 2027-02-01 · Dyslipidemia, Type 2 Diabetes
What this study did
NCT03313752 · Giaccari Andrea
2017-12-01 – 2022-10-06 · Type2 Diabetes Mellitus, Stable Coronary Artery Disease
What this study did
Chronic Kidney Disease
NCT07624305 · AstraZeneca
2026-09-01 – 2030-07-01 · Renal Insufficiency, Chronic
What this study did
NCT07025629 · Assistance Publique - Hôpitaux de Paris
2025-12-02 – 2029-01-15 · Heart Failure and Chronic Kidney Disease Post-ICU
What this study did
NCT06268873 · AstraZeneca
2024-03-29 – 2028-02-24 · Chronic Kidney Disease and Hypertension
What this study did
NCT05944016 · University Hospital Goettingen
2024-03-25 – 2027-12 · Chronic Kidney Failure in Children and Young Adults
What this study did
NCT05374291 · University Medical Center Groningen
2022-11-08 – 2027-07 · Kidney Disease, Chronic, Renal Transplant Failure, Heart Failure, Kidney Failure, Death
What this study did
NCT06820567 · Assiut University
2025-03-01 – 2027-05-01 · Chronic Kidney Diseases, Diabetes Type 2
What this study did
NCT07598864 · Chittagong Medical College
2026-05-01 – 2027-05-01 · Diabetic Nephropathy
What this study did
NCT06982079 · Ain Shams University
2025-05-01 – 2026-11-01 · Chronic Kidney Disease Stage 5, CKD Stage 4
What this study did
NCT03762850 · Travere Therapeutics, Inc.
2018-12-11 – 2026-08-19 · Immunoglobulin A Nephropathy
What this study did
NCT06421870 · Ain Shams University
2024-03-01 – 2025-07 · Chronic Kidney Diseases
What this study did
NCT05196347 · Kaohsiung Medical University
2022-05-27 – 2024-08-31 · Chronic Kidney Diseases
What this study did
NCT07344922 · Mansoura University
2022-09-01 – 2023-12-01 · Chronic Kidney Disease, Anemia, Cardiovascular Calcification
What this study did
Heart Failure
NCT06677060 · AstraZeneca
2025-03-14 – 2029-12-17 · Heart Failure
What this study did
NCT06304857 · 4th Military Clinical Hospital with Polyclinic, Poland
2024-04-15 – 2027-12-31 · Breast Cancer, Heart Failure
What this study did
NCT06307652 · AstraZeneca
2024-04-12 – 2027-04-16 · Heart Failure and Impaired Kidney Function
What this study did
NCT06434025 · Hospital de Clinicas de Porto Alegre
2024-05-24 – 2026-11-24 · Heart Failure, Systolic, Iron Deficiencies
What this study did
NCT05776043 · Medical University of Warsaw
2022-03-15 – 2025-12-31 · Acute Decompensated Heart Failure
What this study did
NCT06535529 · Helwan University
2024-08-24 – 2025-09-01 · Acute Decompensated Heart Failure
What this study did
NCT06619600 · Hospital Clinic of Barcelona
2021-05-30 – 2025-03-31 · ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus, Heart Failure, Myocardial Fibrosis
What this study did
NCT05618223 · Universitas Sebelas Maret
2022-12-01 – 2023-06-30 · Rheumatic Heart Disease, Heart Failure, Mitral Stenosis
What this study did
NCT04860011 · NHS Greater Glasgow and Clyde
2021-04-27 – 2023-04-03 · Heart Failure
What this study did
NCT04707352 · Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
2021-02-08 – 2023-03-26 · Heart Failure
What this study did
NCT03877224 · AstraZeneca
2019-04-04 – 2020-07-09 · Heart Failure With Preserved Ejection Fraction (HFpEF)
What this study did
NCT03877237 · AstraZeneca
2019-04-09 – 2020-03-07 · Heart Failure With Reduced Ejection Fraction (HFrEF)
What this study did
Type 2 Diabetes
NCT07026968 · CSPC Ouyi Pharmaceutical Co., Ltd.
2025-06-20 – 2026-11-13 · Type 2 Diabetes
What this study did
NCT05345327 · The George Institute
2023-01-01 – 2026-06-30 · Type 2 Diabetes
What this study did
NCT04965935 · University Health Network, Toronto
2021-07-15 – 2024-08-30 · Kidney Transplant Recipients, Post-transplant Diabetes Mellitus, Type 2 Diabetes
What this study did
NCT05296044 · Jeil Pharmaceutical Co., Ltd.
2022-04-05 – 2024-02-28 · Type 2 Diabetes Mellitus
What this study did
NCT05310916 · Nidae Alaa
2022-06-06 – 2023-11 · Diabetic Retinopathy
What this study did
NCT05998525 · Hilda Elizabeth Macías Cervantes
2021-06-21 – 2023-06-01 · Diabete Type 2, Unstable Angina, Myocardial Infarction, Diabetes Mellitus, Type 2
What this study did
NCT04298229 · Vanderbilt University Medical Center
2020-04-01 – 2023-05-17 · Heart Failure, Diabetes Mellitus, Type 2
What this study did
NCT05591235 · Nanjing First Hospital, Nanjing Medical University
2022-11 – 2023-02 · Type2diabetes, Insulin Resistance
What this study did
NCT05159882 · Newsoara Biopharma Co., Ltd.
2021-04-15 – 2022-09-30 · T2DM
What this study did
NCT05109949 · Centro Universitario de Ciencias de la Salud, Mexico
2020-03-30 – 2022-08-01 · Diabetes Mellitus Type 2 Without Complication
What this study did
NCT04634500 · Daewoong Pharmaceutical Co. LTD.
2020-11-18 – 2021-11-03 · T2DM (Type 2 Diabetes Mellitus)
What this study did
NCT03658031 · Hamad Medical Corporation
2019-03-01 – 2021-01-31 · PreDiabetes, Myocardial Infarction, T2DM (Type 2 Diabetes Mellitus), CVD
What this study did
NCT04195243 · Centro Universitario de Ciencias de la Salud, Mexico
2019-12-02 – 2020-12-30 · Type 2 Diabetes Mellitus
What this study did
NCT03608358 · AstraZeneca
2019-02-27 – 2020-08-04 · Type 2 Diabetes Mellitus
What this study did
NCT02725593 · AstraZeneca
2016-06-22 – 2020-04-06 · Type 2 Diabetes
What this study did
NCT02592421 · The University of Texas Health Science Center at San Antonio
2015-10-23 – 2019-10-31 · Type II Diabetes Mellitus
What this study did
Phase 2/3 (26)
Atherosclerotic Cardiovascular Disease
NCT06286878 · University of Sao Paulo
2021-12-08 – 2025-07-30 · Myocardial Infarction, Acute Coronary Syndrome, Diabetes, Ventricular Dysfunction
What this study did
Chronic Kidney Disease
NCT07214818 · Mansoura University
2025-11-15 – 2026-09-06 · Nephrotic Syndrome
What this study did
NCT04764097 · Tan Tock Seng Hospital
2021-06 – 2026-06 · Cardiovascular Diseases, End Stage Renal Disease
What this study did
NCT05713851 · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
2023-01-01 – 2025-01-01 · AKI - Acute Kidney Injury, Biomarkers, Transition to CKD, CKD
What this study did
NCT05998837 · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
2021-04-13 – 2024-09-30 · Chronic Kidney Disease, Diabetes Mellitus, Type 2, Hypertension
What this study did
Heart Failure
NCT07469722 · Hospital de Clinicas de Porto Alegre
2026-03-23 – 2028-07-01 · Acute Heart Failure (AHF), Congestive Heart Failure Acute, Diuretic Effect, Lung Ultrasonography Score, Ultrasonography, Doppler, Point-of-care Ultrasound (POCUS)
What this study did
NCT06783166 · Mansoura University
2024-08-15 – 2025-08-05 · Acute Heart Failure
What this study did
NCT05676684 · Universidade do Porto
2022-09-15 – 2024-11-29 · Heart Failure With Preserved Ejection Fraction
What this study did
NCT05406505 · Mansoura University
2022-04-25 – 2023-07-01 · Acute Heart Failure
What this study did
Type 2 Diabetes
NCT07033585 · Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
2026-06-15 – 2026-11-28 · Type 2 Diabetes
What this study did
NCT03968224 · Centro Medico Nacional Siglo XXI IMSS
2018-08-04 – 2024-07-31 · PreDiabetes, Obesity, Morbid, Diabetes Mellitus, Type 2
What this study did
NCT00663260 · AstraZeneca
2008-06 – 2011-06 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07684326 · Beni-Suef University
2026-07 – 2027-09 · Ascites Hepatic
What this study did
NCT07810998 · Tanta University
2026-09-10 – 2027-05-10 · Poly Cystic Ovary Syndrome
What this study did
NCT06111443 · Chang Gung Memorial Hospital
2023-12-01 – 2026-11-30 · Atrial Fibrillation Recurrent, Catheter Ablation
What this study did
NCT05986136 · Mostafa Bahaa
2023-08-20 – 2026-08-20 · Inflammatory Bowel Diseases
What this study did
Triple Therapy in T1DMactive not recruiting
NCT03899402 · State University of New York at Buffalo
2019-05-01 – 2026-06-30 · Type 1 Diabetes Mellitus
What this study did
NCT05565976 · Jaime Daniel Mondragon
2020-08-01 – 2025-07-01 · Stroke, Ischemic, Mild Cognitive Impairment, Dementia, Vascular, Metabolic Syndrome
What this study did
NCT05241431 · University of Aarhus
2022-02-12 – 2024-04-01 · Aortic Stenosis, Left Ventricle Hypertrophied
What this study did
NCT05162690 · Post Graduate Institute of Medical Education and Research, Chandigarh
2022-05-01 – 2023-12-31 · Diabetic Peripheral Neuropathy
What this study did
NCT04400760 · The University of The West Indies
2020-05-01 – 2022-06-30 · Platelet Dysfunction
What this study did
NCT04393246 · Cambridge University Hospitals NHS Foundation Trust
2020-07-03 – 2022-06-08 · COVID-19
What this study did
NCT05424315 · Omar Younis
2021-10-01 – 2022-04-30 · Anterior MI
What this study did
NCT02113241 · University of Guadalajara
2014-04 – 2015-05 · Metabolic Syndrome X
What this study did
Phase 2 (85)
Atherosclerotic Cardiovascular Disease
NCT07741890 · The Christ Hospital
2026-09-01 – 2029-03-01 · Angina With Non-Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction (CMD)
What this study did
NCT07898709 · Al-Azhar University
2027-01 – 2027-08 · No Reflow Phenomenon, Reperfusion Injuries, Myocardial, Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction, Coronary Artery Disease (CAD), PCI, Sodium Glucose Co-Transporter 2 Inhibitors, Empagliflozin, Dapagliflozin
What this study did
Chronic Kidney Disease
NCT06072326 · University Medical Center Groningen
2027-01 – 2030-01 · Type 1 Diabetes Mellitus With Diabetic Nephropathy
What this study did
NCT06155604 · The University of Hong Kong
2023-01-04 – 2026-12-31 · Lupus Nephritis, Chronic Kidney Diseases
What this study did
NCT07222917 · AstraZeneca
2025-12-05 – 2026-12-10 · Chronic Kidney Disease and Hypertension
What this study did
NCT05179668 · Medical University of Vienna
2022-10-01 – 2026-02-28 · Kidney Failure, Hemodialysis, Diabetes Mellitus, Type 2, Chronic Kidney Disease, Left Ventricular Hypertrophy
What this study did
NCT06897605 · Mansoura University
2025-04-01 – 2025-10 · Chronic Kidney Disease(CKD), Anemia, Kidney Disease, Chronic
What this study did
NCT06350123 · AstraZeneca
2024-05-01 – 2025-05-09 · Chronic Kidney Disease
What this study did
NCT05570305 · University Medical Center Groningen
2022-10-06 – 2025-03-05 · Chronic Kidney Diseases
What this study did
NCT05359263 · Tor Biering-Sørensen
2022-06-08 – 2025-02-18 · Chronic Kidney Diseases
What this study did
NCT04930549 · University Hospital, Rouen
2022-10-18 – 2024-09-23 · Renal Insufficiency, Chronic
What this study did
NCT05710367 · Albina Nowak, MD
2023-08 – 2024-08 · Fabry Disease
What this study did
NCT04794517 · Mario Negri Institute for Pharmacological Research
2021-11-08 – 2024-05-07 · Chronic Kidney Diseases
What this study did
NCT04595370 · AstraZeneca
2021-01-26 – 2023-09-22 · Heart Failure, Chronic Kidney Disease
What this study did
NCT04724837 · AstraZeneca
2021-04-28 – 2023-06-01 · Chronic Kidney Disease
What this study did
NCT05250752 · Holbaek Sygehus
2021-11-18 – 2022-12-31 · End Stage Renal Disease, Peritoneal Dialysis Complication
What this study did
NCT03190694 · Hiddo Lambers Heerspink
2017-11-12 – 2019-12-01 · Chronic Kidney Diseases, Proteinuria
What this study did
Heart Failure
NCT07273838 · Yale University
2026-03-05 – 2029-10-31 · Heart Failure, Acute Kidney Injury
What this study did
NCT07245069 · University Medical Centre Ljubljana
2025-02-01 – 2029-02 · Heart Failure, Anthracycline-induced Cardiac Toxicity, Endothelial Function (FMD), Arterial Stiffness, Breast Cancer
What this study did
NCT06762964 · Mayo Clinic
2025-05-16 – 2027-02 · Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure With Preserved Ejection Fraction
What this study did
NCT04640493 · Columbia University
2023-12 – 2025-08 · Heart Failure, Sleep Disordered Breathing
What this study did
NCT06012266 · Centre Hospitalier Universitaire Vaudois
2024-08 – 2025-08 · Heart Failure
What this study did
NCT05420285 · Assistance Publique - Hôpitaux de Paris
2022-06-26 – 2024-05 · Heart Failure, Reduced Ejection Fraction
What this study did
NCT04782245 · Hospices Civils de Lyon
2022-09 – 2024-04 · End-stage Heart Failure
What this study did
NCT04956809 · University of Pennsylvania
2021-10-22 – 2023-06-01 · HFrEF
What this study did
NCT04730947 · Mayo Clinic
2021-02-24 – 2022-11-17 · Heart Failure With Preserved Ejection Fraction
What this study did
NCT05330013 · National Heart, Lung, and Blood Institute (NHLBI)
2022-06-23 – 2022-06-23 · Myocardial Dysfunction, Heart Failure, Inflammation
What this study did
NCT04475042 · Mariëlle Scheffer
2020-07-01 – 2022-05 · Heart Failure, Diastolic
What this study did
Type 2 Diabetes
NCT07902726 · University Health Network, Toronto
2026-12-01 – 2028-12-01 · T2D
What this study did
NCT04451837 · Region Skane
2020-09-10 – 2026-12-31 · Type2 Diabetes
What this study did
NCT07515391 · Dasman Diabetes Institute
2019-10-22 – 2026-10-22 · Bariatric Surgery Candidate, Type2 Diabetes
What this study did
NCT05833958 · George Medicines PTY Limited
2024-09 – 2025-09 · Type 2 Diabetes
What this study did
NCT05268926 · University Medical Center Groningen
2022-02-03 – 2023-02-02 · Albuminuria
What this study did
NCT03714594 · University of Pisa
2018-07-24 – 2022-08-31 · Type2 Diabetes Mellitus
What this study did
NCT04304560 · Damanhour University
2020-03 – 2021-04 · Heart Failure With Reduced Ejection Fraction (HFrEF), Diabete Type 2, Cardiomyopathies
What this study did
NCT02558270 · Medical University of Vienna
2016-06 – 2018-06 · Type 2 Diabetes, Metabolically Healthy Controls
What this study did
NCT00976495 · AstraZeneca
2009-10 – 2010-11 · Type 2 Diabetes Mellitus
What this study did
NCT00831779 · AstraZeneca
2009-04 – 2010-08 · Type 2 Diabetes Mellitus
What this study did
NCT00972244 · AstraZeneca
2009-08 – 2010-05 · Type 2 Diabetes Mellitus
What this study did
NCT00263276 · AstraZeneca
2005-12 – 2007-02 · Type 2 Diabetes
What this study did
NCT00162305 · AstraZeneca
2005-04 – 2005-08 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07923630 · The University of Texas Health Science Center at San Antonio
2027-01 – 2031-02 · Aging, Functional Decline
What this study did
NCT07310433 · Yung NA
2026-05-01 – 2030-04-30 · Prostate Cancer, Metastatic Prostate Cancer
What this study did
NCT07539259 · University College, London
2026-12 – 2030-02-28 · Aortic Stenosis
What this study did
NCT07516847 · Seug yun Yoon, MD
2026-09 – 2029-09 · Myelodysplastic Syndromes (MDS), Anemia
What this study did
NCT07729592 · Sun Yat-sen University
2026-07 – 2029-07 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07174687 · Washington University School of Medicine
2025-12-02 – 2028-06 · Retinal Degeneration, Retinal Diseases, Eye Diseases, Geographic Atrophy, Pathological Conditions, Anatomical
What this study did
NCT06420167 · Barbara Ann Karmanos Cancer Institute
2024-07-11 – 2028-04 · Renal AL Amyloidosis
What this study did
NCT05938712 · University Health Network, Toronto
2023-10-24 – 2028-03-01 · Kidney Transplant Recipients
What this study did
NCT07225465 · St Vincent's Hospital Melbourne
2026-02 – 2028-02 · Type 1 Diabetes Mellitus
What this study did
Phase 1/2 (9)
Chronic Kidney Disease
NCT07678203 · Hospital Civil Juan I. Menchaca
2026-05-28 – 2027-02-26 · Lupus Nephritis (LN), Chronic Kidney Disease, SGLT 2 Inhibitors, Systemic Lupus Erythematosus
What this study did
NCT05719714 · Northwestern University
2024-01-16 – 2026-09-30 · Chronic Kidney Diseases, Heart Failure With Preserved Ejection Fraction, Kidney Diseases, Heart Failure
What this study did
Type 2 Diabetes
NCT07020377 · Amira Bisher,PhD
2024-01-15 – 2025-12-30 · Diabetes Mellitus, Non Alcholic Fatty Liver Disease
What this study did
Other / comorbidity
NCT07901309 · Tanta University
2026-10-30 – 2027-07-01 · Rheumatoid Arthritis (RA
What this study did
NCT07239011 · Tanta University
2025-11-01 – 2026-12-20 · Depression
What this study did
NCT06113900 · Ain Shams University
2023-12-01 – 2025-01-30 · Lupus Nephritis
What this study did
NCT04545411 · University of California, San Diego
2021-02-22 – 2022-10-31 · Type 1 Diabetes
What this study did
NCT04401904 · The University of Texas Health Science Center at San Antonio
2020-06-25 – 2022-09-14 · Aging
What this study did
NCT03801642 · Jeff Burns, MD
2019-01-29 – 2022-07-07 · Alzheimer Disease
What this study did
Phase 1 (81)
Atherosclerotic Cardiovascular Disease
NCT05762952 · University of Virginia
2023-06-06 – 2025-08-05 · Myocardial Ischemia
What this study did
Chronic Kidney Disease
NCT04991571 · AstraZeneca
2021-07-29 – 2021-10-22 · Chronic Kidney Disease
What this study did
Heart Failure
NCT06639087 · AstraZeneca
2024-09-27 – 2025-05-29 · Renal Impairment, Heart Failure
What this study did
Type 2 Diabetes
NCT07034781 · AJU Pharm Co., Ltd.
2025-08 – 2025-11 · Type2 Diabetes Mellitus
What this study did
NCT07044765 · AJU Pharm Co., Ltd.
2025-08 – 2025-11 · Type2 Diabetes Mellitus
What this study did
NCT05262257 · The First Affiliated Hospital with Nanjing Medical University
2022-04-01 – 2023-12-30 · Type2 Diabetes
What this study did
NCT06063109 · THPharm Corp.
2023-10-09 – 2023-11-09 · Hypertension, Diabetes Mellitus, Type 2
What this study did
NCT05411965 · Boryung Pharmaceutical Co., Ltd
2022-04-28 – 2022-07-03 · Diabetes Mellitus, Type 2
What this study did
NCT05266404 · AstraZeneca
2022-03-21 – 2022-05-31 · Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)
What this study did
NCT03766724 · Dong-A ST Co., Ltd.
2018-11-22 – 2019-01-18 · Type2 Diabetes
What this study did
NCT03565458 · LG Chem
2018-04-05 – 2018-12-22 · Type 2 Diabetes Mellitus
What this study did
NCT02223065 · AstraZeneca
2014-09 – 2014-12 · Type 2 Diabetes Mellitus
What this study did
NCT01525238 · AstraZeneca
2012-07-01 – 2014-09-01 · Type 2 Diabetes Mellitus
What this study did
NCT02060201 · AstraZeneca
2014-02 – 2014-05 · Type 2 Diabetes Mellitus
What this study did
NCT01535677 · AstraZeneca
2013-04 – 2013-07 · Type 2 Diabetes Mellitus
What this study did
NCT01662999 · AstraZeneca
2012-08 – 2012-11 · Type 2 Diabetes Mellitus
What this study did
NCT01135446 · AstraZeneca
2010-05 – 2010-06 · Type 2 Diabetes
What this study did
NCT01055652 · AstraZeneca
2010-01 – 2010-04 · Type 2 Diabetes Mellitus
What this study did
NCT01068756 · AstraZeneca
2010-03 – 2010-04 · Type 2 Diabetes Mellitus
What this study did
NCT00908271 · AstraZeneca
2009-07 – 2009-08 · Type 2 Diabetes Mellitus
What this study did
NCT00904176 · AstraZeneca
2009-06 – 2009-08 · Type 2 Diabetes Mellitus
What this study did
NCT00842556 · AstraZeneca
2009-03 – 2009-05 · Type 2 Diabetes Mellitus
What this study did
NCT00839683 · AstraZeneca
2009-02 – 2009-03 · Type 2 Diabetes Mellitus
What this study did
NCT00554450 · AstraZeneca
2006-03 – 2008-10 · Diabetes Mellitus, Type 2
What this study did
NCT00562250 · AstraZeneca
2008-05 – 2008-08 · Diabetes Mellitus, Type 2
What this study did
NCT00538174 · AstraZeneca
2007-11 – 2008-05 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT05521984 · Washington University School of Medicine
2023-04-03 – 2031-06-30 · Pediatric Brain Tumor, Pediatric Solid Tumor
What this study did
NCT07235280 · Jonsson Comprehensive Cancer Center
2025-12-02 – 2029-06-29 · Lung Adenocarcinoma, Stage IA1 Lung Cancer American Joint Committee on Cancer (AJCC) v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Lung Cancer
What this study did
NCT06759909 · Assiut University
2025-01-03 – 2028-12-22 · Dapagliflozin (Forxiga), Atrial Fibrillation (AF)
What this study did
NCT05989347 · Yale University
2024-10-15 – 2027-12 · Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer
What this study did
NCT06373523 · Post Graduate Institute of Medical Education and Research, Chandigarh
2024-01-15 – 2026-12-31 · Hepatic Steato-Fibrosis, Non-Alcoholic Fatty Liver Disease
What this study did
NCT06612086 · Assiut University
2024-10-25 – 2026-10-10 · Pulmonary Hypertension
What this study did
NCT07754331 · AstraZeneca
2026-08-06 – 2026-10-06 · Kidney Failure
What this study did
NCT07083401 · Boryung Pharmaceutical Co., Ltd
2025-07-05 – 2026-07-05 · Diabete Mellitus
What this study did
NCT07083388 · Boryung Pharmaceutical Co., Ltd
2025-07-03 – 2026-07-03 · Diabetes Mellitus
What this study did
NCT07396844 · LG Chem
2026-06-11 – 2026-06-26 · Healthy, Fasting, Fed
What this study did
NCT07404137 · AstraZeneca
2026-02-16 – 2026-04-02 · Healthy Participants
What this study did
NCT04887935 · Washington University School of Medicine
2024-06-04 – 2025-11-26 · Prostate Cancer, Cancer of Prostate
What this study did
NCT06812429 · Washington University School of Medicine
2024-05-08 – 2025-04-05 · Inflammation
What this study did
Phase 4 (177)
Atherosclerotic Cardiovascular Disease
NCT07254572 · National Institute of Cardiology, Warsaw, Poland
2025-07-10 – 2029-08-01 · Coronary Artery Disease, PreDiabetes
What this study did
NCT07614230 · Junjie Yang
2026-01-01 – 2028-12-31 · Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease, Atherosclerosis
What this study did
NCT07351643 · Shenyang Northern Hospital
2026-06-25 – 2027-06-30 · ACS (Acute Coronary Syndrome), SGLT2 Inhibitors
What this study did
NCT05457933 · Medanta, The Medicity, India
2022-07-29 – 2023-01-14 · Type2diabetes, Coronary Artery Disease
What this study did
NCT04330079 · CHEOL WHAN LEE, M.D., Ph.D
2020-05-21 – 2021-04-08 · Coronary Artery Disease, Prediabetic State
What this study did
NCT02919345 · University of Campinas, Brazil
2017-01 – 2019-03 · Diabetes Mellitus, Type 2, Coronary Artery Disease, Carotid Artery Diseases
What this study did
NCT03398577 · Sheba Medical Center
2018-02-01 – 2018-12-31 · Coronary Disease With Diabetes Mellitus
What this study did
NCT02577159 · Osaka University
2015-07-01 – 2018-08-31 · Diabetes Mellitus, Type 2
What this study did
NCT03074630 · Amsterdam UMC, location VUmc
2016-05 – 2018-04 · Diabetes Mellitus, Type 2, Hypercholesterolemia
What this study did
Chronic Kidney Disease
NCT07547878 · Baylor Research Institute
2026-04-08 – 2029-03-31 · Chronic Kidney Disease, Type 2 Diabetes
What this study did
NCT06642272 · Herlev and Gentofte Hospital
2024-10-10 – 2028-12-31 · Diabetes Mellitus, Type 2, Heart Failure, Chronic Kidney Diseases
What this study did
NCT07239570 · Peter Rossing
2025-06-20 – 2028-06 · Chronic Kidney Disease(CKD)
What this study did
NCT07405216 · Centenario Hospital Miguel Hidalgo
2026-04-23 – 2027-10-30 · Chronic Kidney Disease (Mild to Moderate), Albuminuria, Adolescent, Sodium Glucose Co-Transporter 2 Inhibitors
What this study did
NCT06954090 · Steno Diabetes Center Copenhagen
2025-11-20 – 2027-05-31 · Type 2 DM, Type 2 DM /Diabetic Nephropathy, Albuminuria
What this study did
NCT06610526 · AstraZeneca
2024-08-23 – 2027-05-31 · Chronic Kidney Disease
What this study did
NCT06560801 · University of Erlangen-Nürnberg Medical School
2023-07-28 – 2026-12-31 · Chronic Kidney Diseases
What this study did
NCT06532682 · The First Affiliated Hospital with Nanjing Medical University
2024-07-01 – 2026-10-01 · Diabetic Kidney Disease, Type 1 Diabetes
What this study did
NCT05685394 · University of Campinas, Brazil
2023-01-24 – 2024-12-01 · End-stage Kidney Disease
What this study did
NCT05966818 · Ain Shams University
2023-08-01 – 2024-03-01 · Nephrotic Syndrome
What this study did
NCT05225077 · Dong-A University
2022-01-01 – 2023-12-31 · Renal Insufficiency, Chronic, Cardiac Catheterization, Percutaneous Coronary Intervention
What this study did
NCT05735197 · Mansoura University
2022-09-01 – 2023-11-01 · Chronic Kidney Diseases, Bone Diseases, Metabolic
What this study did
NCT06026787 · Ain Shams University
2022-08-01 – 2023-08-01 · Nephrotic Syndrome, Sodium-Glucose Transporter 2 Inhibitors
What this study did
NCT06326034 · Mohammed Mahmood Mohammed
2022-05-01 – 2023-01-01 · Diabetic Nephropathy Type 2
What this study did
NCT04531397 · Children's Hospital of Fudan University
2021-01-01 – 2022-12-31 · Proteinuria, Chronic Kidney Diseases
What this study did
NCT05343078 · University of Campinas, Brazil
2022-04-25 – 2022-10-01 · End-stage Renal Disease
What this study did
NCT06374043 · University Medical Center Groningen
2021-05-11 – 2022-09-13 · Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Diabetes, Diabetes Complications, Albuminuria, Chronic Kidney Diseases, Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, CKD, Proteinuria
What this study did
NCT02682563 · M.H.H. Kramer
2016-02 – 2018-09 · Diabetes Mellitus, Type 2, Diabetic Nephropathies
What this study did
NCT02914691 · Peter Rossing
2015-08 – 2017-07-05 · Type 2 Diabetes, Diabetic Nephropathy
What this study did
NCT02585804 · University Health Network, Toronto
2015-09 – 2017-04-24 · Focal Segmental Glomerulosclerosis
What this study did
Heart Failure
NCT07482943 · The University of Hong Kong
2026-07-01 – 2028-07 · Fontan, Heart Failure, Dapagliflozin, Cardiovascular Diseases, Sodium-GLucose coTransporter-2 Inhibitors
What this study did
NCT06578520 · Fundación para la Investigación del Hospital Clínico de Valencia
2024-07-30 – 2026-12-31 · Heart Failure
What this study did
NCT07926958 · Universidade do Porto
2024-03-11 – 2026-12 · Heart Failure, Acute Decompensated Heart Failure (ADHF)
What this study did
NCT07076615 · May Mohamed Abdalla
2025-08-01 – 2026-05-31 · Acute Decompensated Heart Failure (ADHF)
What this study did
NCT05741658 · Johns Hopkins University
2023-11-08 – 2026-03-10 · Heart Failure
What this study did
NCT04707261 · Xiangtan Central Hospital
2021-08-06 – 2026-01-01 · Anemia, Heart Failure
What this study did
NCT04363697 · The TIMI Study Group
2020-09-24 – 2025-06-02 · Acute Heart Failure, Heart Failure
What this study did
NCT05550441 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2022-11-15 – 2024-11-15 · Heart Failure
What this study did
NCT04869124 · Frank Ruschitzka
2021-02-15 – 2024-10-28 · Heart Failure,Congestive
What this study did
NCT06365541 · The People's Hospital of Gaozhou
2024-03-01 – 2024-08-31 · The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients
What this study did
NCT05816733 · Kun Hua
2023-09-01 – 2024-08-07 · Atrial Fibrillation Recurrence, Cox Maze IV, Atrial Fibrillation, Patients With or Without Heart Failure and Diabetes
What this study did
NCT06012279 · Cairo University
2023-08-01 – 2024-02-26 · Acute Heart Failure
What this study did
NCT04778787 · I.M. Sechenov First Moscow State Medical University
2021-01-01 – 2022-08-01 · Congestive Heart Failure
What this study did
NCT04197635 · Fundación para la Investigación del Hospital Clínico de Valencia
2019-06-01 – 2022-04-19 · Heart Failure With Reduced Ejection Fraction
What this study did
NCT04249778 · Emory University
2020-07-29 – 2022-03-03 · Heart Failure, Diabetes
What this study did
NCT04570865 · Scripps Health
2020-12-01 – 2022-02-01 · Heart Failure, Systolic
What this study did
NCT04080518 · National Heart Centre Singapore
2019-11-11 – 2021-11-10 · Diabetes Mellitus, Heart Failure
What this study did
NCT03030235 · Saint Luke's Health System
2017-03-01 – 2021-08-13 · Chronic Heart Failure With Preserved Systolic Function
What this study did
NCT04575675 · Cheng-Hsin General Hospital
2020-05-29 – 2020-12-30 · Hypotension, Heart Failure
What this study did
NCT04385589 · Assiut University
2020-05-01 – 2020-12-20 · Heart Failure
What this study did
NCT02653482 · Saint Luke's Health System
2016-03-03 – 2019-06-28 · Chronic Heart Failure With Reduced Systolic Function
What this study did
Early phase / not applicable (48)
Chronic Kidney Disease
NCT07491042 · Oman Ministry of Health
2026-04-01 – 2027-01-31 · End Stage Chronic Renal Failure
What this study did
NCT05965440 · Hospices Civils de Lyon
2023-11-20 – 2026-02-02 · Chronic Kidney Diseases
What this study did
NCT06187493 · Assiut University
2024-01-01 – 2025-12-31 · Diabetic Kidney Disease
What this study did
NCT06344247 · RenJi Hospital
2023-09-01 – 2025-12-01 · Obesity, Chronic Kidney Diseases
What this study did
NCT06165601 · University Hospital, Montpellier
2024-01-04 – 2025-10-25 · Chronic Kidney Diseases
What this study did
NCT05849220 · Institute of Liver and Biliary Sciences, India
2023-05-15 – 2024-03-30 · NAFLD Cirrhosis
What this study did
Heart Failure
NCT07403955 · Qilu Hospital of Shandong University
2026-02 – 2028-12 · Congestive Heart Failure Acute
What this study did
NCT07392788 · Centre Hospitalier Universitaire de Besancon
2026-04 – 2028-02 · Acute Heart Failure (AHF)
What this study did
NCT06868797 · Central Hospital, Nancy, France
2025-08-29 – 2027-09-12 · Heart Failure
What this study did
NCT06510270 · Aswan University
2024-08-01 – 2025-10-01 · Heart Failure with Preserved Ejection Fraction
What this study did
NCT05795400 · National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
2022-06-01 – 2025-09-30 · Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Amyloid Cardiomyopathy
What this study did
NCT06778330 · Fayoum University
2025-01-20 – 2025-08-01 · Heart Failure NYHA Class II
What this study did
NCT06915870 · Fatima Maqsood
2024-07-12 – 2025-01-13 · Diabetes Mellitus, Heart Failure
What this study did
NCT04591639 · University of Edinburgh
2020-08-19 – 2025-01-01 · Heart Failure, Diabetic Cardiomyopathies
What this study did
NCT06065280 · Damanhour University
2022-11-01 – 2024-12-30 · Heart Failure, Reduced Ejection Fraction Heart Failure
What this study did
NCT06090487 · Ain Shams University
2024-02-01 – 2024-03-01 · Heart Failure
What this study did
NCT04717986 · Instituto Mexicano del Seguro Social
2021-01-26 – 2023-06-20 · Acute Myocardial Infarction, Cardiovascular Morbidity, Heart Failure, Angina, Unstable
What this study did
NCT05141552 · RenJi Hospital
2022-01-03 – 2022-07-31 · Hemodialysis Complication
What this study did
Type 2 Diabetes
NCT07778719 · The 95th Hospital of Putian,Putian, Fujian, China
2026-10-01 – 2027-12-11 · Type 2 Diabetes, Metabolic Dysfunction-Associated Steatotic Liver Disease
What this study did
NCT07595289 · The Third Xiangya Hospital of Central South University
2026-08-01 – 2027-08-01 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT02969798 · The University of Texas Health Science Center at San Antonio
2014-01-01 – 2027-07 · Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
What this study did
NCT07303556 · Nazarbayev University
2024-12-18 – 2026-11-01 · Heart Failure, Diabete Type 2, Arterial Hypertension
What this study did
NCT02879409 · Weill Cornell Medical College in Qatar
2016-11 – 2026-10-01 · Diabetes Mellitus Type 2
What this study did
NCT07338331 · Galala University
2023-04-04 – 2025-09-19 · Diabete Type 2, Non Alcoholic Fatty Liver
What this study did
NCT06719661 · University of Sulaimani
2024-12-01 – 2025-06-01 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT05335629 · Ain Shams University
2022-06-01 – 2023-10-01 · Myocardial Infarction, Diabetes Mellitus, Type 2, Myocardial Remodeling, Ventricular
What this study did
NCT03961659 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2019-05 – 2021-02 · Type 2 Diabetes Mellitus, Obesity, Cognitive Impairment
What this study did
NCT02613897 · The University of Texas Health Science Center at San Antonio
2016-01 – 2018-06-30 · Diabetes Mellitus, Type 2
What this study did
NCT02420392 · Seoul National University Hospital
2015-02 – 2016-04 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07823972 · Assiut University
2026-11-01 – 2029-01-30 · ASD2(Secundum Atrial Septal Defect)
What this study did
NCT07491718 · University of Edinburgh
2025-08-08 – 2028-08-09 · Takotsubo Cardiomyopathy
What this study did
NCT06009874 · Mohammad Hussien Tantawy Soliman
2023-12-20 – 2028-08 · Myocardial Infarction
What this study did
NCT06398977 · Sichuan Academy of Medical Sciences
2024-03-11 – 2026-12-31 · Peritoneal Dialysis Complication, Renal Function Aggravated, Sodium-glucose Co-transporter-2 Inhibitors
What this study did
NCT07331727 · Shanghai Chest Hospital
2026-01-01 – 2026-12-31 · Atrial Fibrillation (AF)
What this study did
NCT07881796 · Shalamar Hospital
2026-04-15 – 2026-09-15 · Non-Alcoholic Fatty Liver Disease
What this study did
NCT07204743 · Al-Quds University
2025-08-15 – 2026-08 · SGLT 2 Inhibitors, Pediatric Kidney Disease, Proteinuric Diseases, Dapagliflozin (Forxiga)
What this study did
NCT06740786 · Xu Liu
2024-12-10 – 2026-05-01 · Atrial Fibrillation (AF)
What this study did
NCT05042505 · Medanta, The Medicity, India
2022-01-01 – 2026-02-27 · Diabetes Mellitus, Liver Transplant; Complications
What this study did
NCT06433479 · Beijing Anzhen Hospital
2024-07-15 – 2025-07-01 · Atrial Fibrillation
What this study did
NCT05686616 · Samsung Medical Center
2022-04-13 – 2025-03-03 · Tricuspid Regurgitation
What this study did
NCT06147518 · Institute of Liver and Biliary Sciences, India
2023-12-20 – 2024-12-31 · Compensated Cirrhosis, Decompensated Cirrhosis
What this study did
NCT05390307 · Dasman Diabetes Institute
2023-04-01 – 2024-01-01 · Type 1 Diabetes
What this study did
NCT06127212 · Dexa Medica Group
2023-03-08 – 2023-05-06 · Healthy
What this study did
NCT05045274 · Assiut University
2021-12 – 2022-09 · STEMI - ST Elevation Myocardial Infarction, Left Ventricular Systolic Dysfunction
What this study did
NCT02962492 · University at Buffalo
2016-11-01 – 2021-10-24 · Evaluate Ketogenic Stress
What this study did
NCT04923295 · An-Najah National University
2021-06-02 – 2021-07-28 · Peritoneal Dialysis Complication, Ultrafiltration Failure
What this study did
NCT01439854 · The University of Texas Health Science Center at San Antonio
2011-03 – 2018-06-30 · Insulin Sensitivity, Multiple Mitochondrial Dysfunctions Syndrome
What this study did
NCT02777073 · University at Buffalo
2016-03-01 – 2016-12-31 · Type 1 Diabetes
What this study did
Used as active comparator (27)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (12)
Chronic Kidney Disease
NCT06087835 · AstraZeneca
2023-11-07 – 2027-02-18 · Chronic Kidney Disease With High Proteinuria
What this study did
Type 2 Diabetes
NCT06560333 · Eurofarma Laboratorios S.A.
2026-11-30 – 2029-02-28 · Diabetes Mellitus, Type 2
What this study did
NCT07662109 · AstraZeneca
2026-07-06 – 2028-07-05 · Type 2 Diabetes Mellitus
What this study did
NCT07082114 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2025-07-14 – 2027-05-17 · Type 2 Diabetes
What this study did
NCT05886088 · EMS
2024-02 – 2027-01 · Type 2 Diabetes Mellitus
What this study did
NCT06589765 · Shandong Suncadia Medicine Co., Ltd.
2024-09-27 – 2026-05-29 · Type 2 Diabetes
What this study did
NCT06192108 · Eli Lilly and Company
2024-01-10 – 2025-09-26 · Type 2 Diabetes
What this study did
NCT06415773 · Shenzhen HighTide Biopharmaceutical Ltd.
2024-06-04 – 2025-07-25 · T2DM (Type 2 Diabetes Mellitus)
What this study did
NCT05505994 · Daewoong Pharmaceutical Co. LTD.
2022-09-28 – 2024-09 · Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
What this study did
NCT03766750 · EMS
2021-12 – 2023-11 · Type2 Diabetes Mellitus
What this study did
Phase 2 (3)
Chronic Kidney Disease
NCT06942910 · AstraZeneca
2025-05-07 – 2026-09-26 · Chronic Kidney Disease With High Proteinuria
What this study did
NCT05884866 · Klinikum Nürnberg
2023-07-13 – 2026-01-28 · Chronic Renal Failure, Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis, Chronic Kidney Disease Stage 3, Electrolyte and Fluid Balance Conditions
What this study did
Other / comorbidity
NCT04956263 · Youngene Therapeutics Inc., Ltd.
2021-06-17 – 2022-07-19 · Diabetes, Diabetes Mellitus, Type 1, Type1diabetes, Diabetes Mellitus
What this study did
Phase 1 (2)
Phase 4 (8)
Type 2 Diabetes
NCT06642623 · Yonsei University
2024-01-22 – 2030-12-31 · Diabetes Mellitus, Type 2, Cardiovascular Diseases, Kidney Diseases
What this study did
NCT06127433 · Sun Yat-sen University
2023-03-07 – 2024-12-30 · Insulin Pump,Continuous Glucose Monitoring Technology
What this study did
NCT04706637 · Kyung Hee University Hospital at Gangdong
2021-02-01 – 2023-01-31 · Bone Diseases, Metabolic, Diabetes Mellitus, Type 2
What this study did
NCT03970044 · Consano Clinical Research, LLC
2019-07-02 – 2021-06-01 · Diabetes Mellitus, Type 2
What this study did
NCT03361098 · Amsterdam UMC, location VUmc
2017-09-18 – 2020-03-25 · Type 2 Diabetes Mellitus, Obesity
What this study did
Early phase / not applicable (2)
Chronic Kidney Disease
NCT07866235 · Lahore General Hospital
2023-10-11 – 2024-04-10 · Diabetic Nephropathies, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
What this study did
NCT05418465 · The First Affiliated Hospital of Dalian Medical University
2022-01-26 – 2022-12-31 · Diabetic Nephropathies
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 1 (1)
Other / comorbidity
NCT05066516 · Korea University Anam Hospital
2020-06-25 – 2020-10-18 · Diabetes Mellitus
What this study did
Appears in other studies (9)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (4)
Type 2 Diabetes
NCT05226897 · Yooyoung Pharmaceutical Co., Ltd.
2021-07-12 – 2023-06-26 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT07056699 · The University of Texas Health Science Center at San Antonio
2026-07-01 – 2027-06-30 · Type1diabetes
What this study did
Phase 2 (3)
Chronic Kidney Disease
NCT04170543 · AstraZeneca
2019-11-18 – 2023-05-16 · Diabetic Kidney Disease
What this study did
NCT04492722 · AstraZeneca
2020-10-01 – 2022-09-06 · Chronic Kidney Disease
What this study did
Heart Failure
NCT07610174 · Kafrelsheikh University
2025-06-02 – 2026-04-29 · Heart Failure, Heart Valve Prosthesis
What this study did
Phase 4 (1)
Chronic Kidney Disease
NCT06281899 · Anemia Working Group Romania
2022-01-01 – 2027-12-31 · Chronic Kidney Diseases, Type 2 Diabetes Mellitus
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT06241638 · Al-Balqa Applied University
2022-07-01 – 2023-06-30 · Diabetes Mellitus
What this study did

Competitive landscape

This mechanism is crowded: 10 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 2 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Dapagliflozin (Farxiga / Forxiga): this drugApprovedSmall moleculeSGLT2Partial signal
NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02)
NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14)
Acarbose (Precose / Glucobay)
ApprovedUS marketing discontinued
Small moleculeAlpha-glucosidasenot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results).
Alogliptin (Nesina)ApprovedSmall moleculeDPP-4Partial signal
NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed
NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8%
Bexagliflozin (Brenzavvy)ApprovedSmall moleculeSGLT2Reliable signal
NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058)
NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075)
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Partial signal
NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002).
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Colesevelam (Welchol)ApprovedSmall moleculeBile acid sequestrantnot yet gradedNo reviewed efficacy summary in this indication
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04)
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1%
NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results).
Ertugliflozin (Steglatro)ApprovedSmall moleculeSGLT2Reliable signal
NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years
NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001).
Glimepiride (Amaryl)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glipizide (Glucotrol)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glyburide (DiaBeta)ApprovedSmall moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97)
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)Partial signal
NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07)
NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated.
Insulin Efsitora Alfa (Onswik)ApprovedProtein / enzyme therapeuticInsulin receptor (basal)Partial signal
NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545)
NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424)
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)Partial signalNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062)
NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067)
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061)
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptorPartial signal
NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly.
Insulin Icodec (Awiqli)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89)
NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12)
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptorReliable signalFeatured results are non-efficacy only in this race
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptorPartial signal
NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061)
NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042)
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Linagliptin (Tradjenta)ApprovedSmall moleculeDPP-4Partial signal
NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years
NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptorReliable signal
NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07)
NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001)
Lixisenatide (Adlyxin / Lyxumia)ApprovedPeptideGLP-1 receptorPartial signal
NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054)
NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119)
Metformin (Glucophage)
ApprovedUS marketing discontinued
Small moleculeAMPKReliable signal
NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%)
Pioglitazone (Actos)ApprovedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
SAR341402ApprovedPeptideInsulin receptorPartial signal
NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041)
Saxagliptin (Onglyza)
ApprovedUS marketing discontinued
Small moleculeDPP-4Reliable signal
NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07)
NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1)
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Sitagliptin (Januvia)ApprovedSmall moleculeDPP-4Partial signal
NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03)
NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3)
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)Partial signal
NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579
NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229)
Miglitol (Glyset)US approval withdrawnSmall moleculeAlpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
Repaglinide (Prandin / NovoNorm)US approval withdrawnSmall moleculeSUR1 (short-acting)Partial signalNo reviewed efficacy summary in this indication
AlbenatidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorWeak signal
NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo
Anagliptin (Suiny)Phase 3Small moleculeDPP-4Partial signal
NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo.
NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established.
ASC30Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 3Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Reliable signal
NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo
NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
BofanglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21).
Chiglitazar (Bilessglu)Phase 3Small moleculePPAR (pan-agonist)Reliable signal
NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008.
NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740)
CofrogliptinPhase 3Small moleculeDPP-4Reliable signal
NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin
NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001
Dapagliflozin / Linagliptin (Dapalina)Phase 3Small moleculeSGLT2;DPP-4Partial signal
NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001
Dorzagliatin (Huatangning)Phase 3Small moleculeGlucokinasePartial signal
NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30).
EfpeglenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care).
Efsubaglutide AlfaPhase 3Protein / enzyme therapeuticGLP-1 receptorReliable signal
NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero.
NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001)
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signal
NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2Reliable signal
NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35%
NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%).
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Evogliptin (Suganon)Phase 3Small moleculeDPP-4Reliable signal
NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001)
NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority.
Exendin-4 Fc Fusion (JY09)Phase 3Protein / enzyme therapeuticGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Gemigliptin (Zemiglo)Phase 3Small moleculeDPP-4Reliable signal
NCT03842267: LSM difference in HbA1c change at week 24 (gemigliptin add-on vs placebo, on background dapagliflozin + metformin): −0.66% (SE 0.07), 95% CI −0.80% to −0.52%.
NCT02831361: Change in HbA1c from baseline at Week 24, between-group mean difference (gemigliptin 50 mg vs placebo, added to insulin ± metformin): -0.7 percentage points (95% CI -0.9 to -0.4), p<0.0001
GosogliptinPhase 3Small moleculeDPP-4Partial signal
NCT03088670: Primary, HbA1c change at week 12 (monotherapy stage): 8.61% to 7.41% with gosogliptin vs 8.7% to 7.34% with vildagliptin (each p<0.05 vs baseline); the between-group difference was not significant and no non-inferiority test or margin is reported. Week 36 not reported. Target HbA1c <=7.0%: 41% vs 44% (p=0.53).
GZR33Phase 3PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
HenagliflozinPhase 3Small moleculeSodium-glucose cotransporter 2 (SGLT2)Reliable signal
NCT04390295: Placebo-adjusted LS mean HbA1c change at Week 24: -0.76% (5 mg) and -0.80% (10 mg) vs placebo, both P < .0001.
NCT03159052: Placebo-adjusted LS mean HbA1c change at Week 24: -0.91% (5 mg) and -0.94% (10 mg) vs placebo, both P < .001.
Janagliflozin (Huiyoujing)Phase 3Small moleculeSGLT2Reliable signal
NCT03811548: Placebo-adjusted HbA1c change at week 24: janagliflozin 25 mg -0.80% (95% CI -0.98 to -0.62), 50 mg -0.88% (95% CI -1.06 to -0.70); P<0.001 for both (Ji et al., Diabetes Obes Metab 2023)
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistReliable signalNo reviewed efficacy summary in this indication
ObicetrapibPhase 3Small moleculeCETPnot yet gradedNo reviewed efficacy summary in this indication
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptorPartial signal
NCT05872620: Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001)
NCT05803421: Primary endpoint, time to first MACE-4 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for unstable angina), non-inferiority with margin 1.8 on the upper 95% CI bound of the hazard ratio: 57/1358 (4.2%) orforglipron vs 67/1343 (5.0%) insulin glargine; HR 0.84 (95% CI 0.59 to 1.20; p<0.0001 for non-inferiority), met.
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)Partial signal
NCT05929079: Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract.
NCT06354660: Change in HbA1c from baseline (7.9%) at Week 40: 4 mg -1.7%, 9 mg -2.0%, 12 mg -1.9%, placebo -0.8%; retatrutide met the primary endpoint.
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)Partial signal
NCT06650007: Change in HbA1c from baseline (efficacy estimand): maximum mean reduction of 2.67% with once-weekly ribupatide injection (4 mg and 2 mg) vs placebo
NCT06649344: Primary, HbA1c change from baseline to week 36 (non-inferiority vs semaglutide 1 mg, efficacy estimand): ribupatide 4 mg -2.78%, 2 mg -2.34%, semaglutide -2.29%; non-inferiority achieved for both doses (margin and CI not published), and 4 mg statistically superior to semaglutide, met.
Safiglipron (HRS-7535)Phase 3Small moleculeGLP-1 receptorPartial signal
NCT06589765: Primary, HbA1c change from baseline at week 32 vs dapagliflozin 10 mg (non-inferiority margin 0.4%, primary non-inferiority estimand): 30 mg -0.30% (95% CI -0.51 to -0.09), 60 mg -0.22% (95% CI -0.44 to -0.01), 90 mg -0.40% (95% CI -0.62 to -0.19); non-inferiority met for all three doses (all P<0.0001). Superiority (treatment policy estimand): 90 mg -0.25% (95% CI -0.45 to -0.05; one-sided P=0.0067), 60 mg not significant (P=0.0789).
NCT06672172: OUTSTAND-1 phase 3 T2D trial (placebo-controlled, diet-and-exercise inadequately controlled); enrollment (284) matches this listing exactly. Primary endpoint (HbA1c reduction at Week 32 vs placebo, across 30/60/90mg doses) was met: 1.40-1.68% reduction vs 0.06% for placebo.
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
DA-2811Phase 2Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
Tofogliflozin (Apleway / Deberza)Phase 2Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
OlorigliflozinPhase 1Small moleculeSGLT2Weak signalNo reviewed efficacy summary in this indication

Large race: only the 77 furthest-along competitors are listed; 73 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(89 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Farxiga / Forxiga (Dapagliflozin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (11)
November 2026 (2)
Phase 2/3Atrial Fibrillation Recurrent, Catheter AblationActive not recruiting
Est. primary completion 2026-11-30 · NCT06111443 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesEnrolling by invitation
Est. primary completion 2026-11-30 · NCT06954090 · CT.gov ↗
What to watch
December 2026 (9)
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2026-12 · NCT07311551 · CT.gov ↗
What to watch
Phase 4Heart FailureActive not recruiting
Est. primary completion 2026-12-01 · NCT06578520 · CT.gov ↗
What to watch
Phase 2Chronic Kidney DiseaseActive not recruiting
Est. primary completion 2026-12-10 · NCT07222917 · CT.gov ↗
What to watch
Phase 1Dapagliflozin (Forxiga), Atrial Fibrillation (AF)Not yet recruiting
Est. primary completion 2026-12-22 · NCT06759909 · CT.gov ↗
What to watch
Phase 2Chronic Kidney DiseaseRecruiting
Est. primary completion 2026-12-31 · NCT06155604 · CT.gov ↗
What to watch
Phase 3Heart FailureRecruiting
Est. primary completion 2026-12-31 · NCT06304857 · CT.gov ↗
What to watch
Phase 3Pediatric Hereditary Kidney DiseasesRecruiting
Est. primary completion 2026-12-31 · NCT06890143 · CT.gov ↗
What to watch
Phase 4Congenital Heart Disease, Repaired Tetralogy of Fallot (rTOF), Pulmonary Regurgitation, Sodium-glucose Cotransporter 2 (SGLT2) Inhibitor …Recruiting
Est. primary completion 2026-12-31 · NCT06668389 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesNot yet recruiting
Est. primary completion 2026-12-31 · NCT07595289 · CT.gov ↗
What to watch
2027 (39)
January 2027 (2)
Phase 3STEMI - ST Elevation Myocardial Infarction, Epicardial FatRecruiting
Est. primary completion 2027-01 · NCT07297589 · CT.gov ↗
What to watch
Phase 1/2Chronic Kidney DiseaseActive not recruiting
Est. primary completion 2027-01-28 · NCT07678203 · CT.gov ↗
What to watch
February 2027 (3)
Phase 2Heart FailureRecruiting
Est. primary completion 2027-02 · NCT06762964 · CT.gov ↗
What to watch
Early phase / not applicableHeart FailureRecruiting
Est. primary completion 2027-02-28 · NCT06868797 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesRecruiting
Est. primary completion 2027-02-28 · NCT02969798 · CT.gov ↗
What to watch
April 2027 (4)
Phase 2Renal AL AmyloidosisRecruiting
Est. primary completion 2027-04 · NCT06420167 · CT.gov ↗
What to watch
Phase 3Diabetes Mellitus, Atrial FibrillationRecruiting
Est. primary completion 2027-04 · NCT05174052 · CT.gov ↗
What to watch
Phase 3Heart FailureActive not recruiting
Est. primary completion 2027-04-16 · NCT06307652 · CT.gov ↗
What to watch
Phase 2/3Poly Cystic Ovary SyndromeNot yet recruiting
Est. primary completion 2027-04-30 · NCT07810998 · CT.gov ↗
What to watch
May 2027 (3)
Phase 3Type 2 DiabetesNot yet recruiting
Est. primary completion 2027-05-01 · NCT07598864 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-05-30 · NCT07405216 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseActive not recruiting
Est. primary completion 2027-05-31 · NCT06610526 · CT.gov ↗
What to watch
June 2027 (6)
Phase 2Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2027-06 · NCT07898709 · CT.gov ↗
What to watch
Phase 3ST Elevation Myocardial Infarction, Myocardial InfarctionRecruiting
Est. primary completion 2027-06 · NCT06174753 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-06-01 · NCT07614230 · CT.gov ↗
What to watch
Phase 1/2Rheumatoid Arthritis (RANot yet recruiting
Est. primary completion 2027-06-30 · NCT07901309 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-06-30 · NCT06054035 · CT.gov ↗
What to watch
Phase 4Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2027-06-30 · NCT07351643 · CT.gov ↗
What to watch
July 2027 (4)
Phase 2Acute Kidney InjuryRecruiting
Est. primary completion 2027-07 · NCT06528405 · CT.gov ↗
What to watch
Phase 2/3Ascites HepaticRecruiting
Est. primary completion 2027-07 · NCT07684326 · CT.gov ↗
What to watch
Phase 3Heart FailureActive not recruiting
Est. primary completion 2027-07 · NCT05374291 · CT.gov ↗
What to watch
Phase 2Large Vessel Vasculitis, Giant Cell Arteritis (GCA), Takayasu ArteritisRecruiting
Est. primary completion 2027-07-01 · NCT06887062 · CT.gov ↗
What to watch
August 2027 (1)
Phase 4Atrial Fibrillation, SGLT2 Inhibitor, DC CardioversionRecruiting
Est. primary completion 2027-08-01 · NCT07776054 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-09 · NCT05944016 · CT.gov ↗
What to watch
October 2027 (4)
Early phase / not applicableMyocardial InfarctionRecruiting
Est. primary completion 2027-10 · NCT06009874 · CT.gov ↗
What to watch
Phase 2Kidney Transplant RecipientsRecruiting
Est. primary completion 2027-10-01 · NCT05938712 · CT.gov ↗
What to watch
Phase 4MAFLD in Prediabetes and DiabetesNot yet recruiting
Est. primary completion 2027-10-01 · NCT07891234 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesNot yet recruiting
Est. primary completion 2027-10-10 · NCT07778719 · CT.gov ↗
What to watch
November 2027 (3)
Phase 2GlomerulonephritisNot yet recruiting
Est. primary completion 2027-11 · NCT07096986 · CT.gov ↗
What to watch
Phase 4MASH - Metabolic Dysfunction-Associated SteatohepatitisRecruiting
Est. primary completion 2027-11 · NCT07848191 · CT.gov ↗
What to watch
Phase 4Breast CancerRecruiting
Est. primary completion 2027-11-01 · NCT07436663 · CT.gov ↗
What to watch
December 2027 (8)
Phase 1Breast Cancer, Hyperinsulinism, HER2-negative Breast CancerRecruiting
Est. primary completion 2027-12 · NCT05989347 · CT.gov ↗
What to watch
Phase 2Retinal Degeneration, Retinal Diseases, Eye Diseases, Geographic Atrophy, Pathological Conditions, AnatomicalRecruiting
Est. primary completion 2027-12 · NCT07174687 · CT.gov ↗
What to watch
Phase 2Rheumatoid Arthritis (RA)Not yet recruiting
Est. primary completion 2027-12 · NCT07864688 · CT.gov ↗
What to watch
Phase 3Atrial Fibrillation (AF)Recruiting
Est. primary completion 2027-12 · NCT07187570 · CT.gov ↗
What to watch
Early phase / not applicableHeart FailureNot yet recruiting
Est. primary completion 2027-12 · NCT07392788 · CT.gov ↗
What to watch
Early phase / not applicableHeart FailureNot yet recruiting
Est. primary completion 2027-12 · NCT07403955 · CT.gov ↗
What to watch
Phase 3Chronic Coronary Syndrome, Atrial FibrillationRecruiting
Est. primary completion 2027-12-04 · NCT05852704 · CT.gov ↗
What to watch
Phase 4Myocardial InfarctRecruiting
Est. primary completion 2027-12-31 · NCT06562582 · CT.gov ↗
What to watch
2028 (20)
January 2028 (1)
Phase 2/3Heart FailureNot yet recruiting
Est. primary completion 2028-01-31 · NCT07469722 · CT.gov ↗
What to watch
February 2028 (2)
Phase 2Type 1 Diabetes MellitusNot yet recruiting
Est. primary completion 2028-02 · NCT07225465 · CT.gov ↗
What to watch
Phase 3Chronic Kidney DiseaseActive not recruiting
Est. primary completion 2028-02-24 · NCT06268873 · CT.gov ↗
What to watch
June 2028 (3)
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2028-06 · NCT07239570 · CT.gov ↗
What to watch
Phase 1Lung Adenocarcinoma, Stage IA1 Lung Cancer American Joint Committee on Cancer (AJCC) v8, Stage IA2 Lung Cancer AJCC v8 …Recruiting
Est. primary completion 2028-06-29 · NCT07235280 · CT.gov ↗
What to watch
Phase 3COVID - 19, Long COVID Syndrome, SARS CoV-2Not yet recruiting
Est. primary completion 2028-06-30 · NCT06907251 · CT.gov ↗
What to watch
July 2028 (3)
Phase 4Heart FailureRecruiting
Est. primary completion 2028-07 · NCT07482943 · CT.gov ↗
What to watch
Phase 4Lupus Nephritis (LN)Recruiting
Est. primary completion 2028-07-01 · NCT07323524 · CT.gov ↗
What to watch
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2028-07-14 · NCT07662044 · CT.gov ↗
What to watch
August 2028 (3)
Phase 4Gestational Hypertension, Hypertension in Pregnancy, Pre-Eclampsia, Superimposed Pre-Eclampsia, Cardiovascular ComplicationRecruiting
Est. primary completion 2028-08 · NCT06785116 · CT.gov ↗
What to watch
Early phase / not applicableTakotsubo CardiomyopathyRecruiting
Est. primary completion 2028-08-09 · NCT07491718 · CT.gov ↗
What to watch
Phase 2Heart FailureRecruiting
Est. primary completion 2028-08-31 · NCT07273838 · CT.gov ↗
What to watch
September 2028 (2)
Early phase / not applicableASD2(Secundum Atrial Septal Defect)Not yet recruiting
Est. primary completion 2028-09-01 · NCT07823972 · CT.gov ↗
What to watch
Phase 3Heart Transplant Failure, Kidney FailureActive not recruiting
Est. primary completion 2028-09-30 · NCT05321706 · CT.gov ↗
What to watch
October 2028 (1)
Phase 4Kidney Transplant; Complications, Vascular Diseases, DiabetesRecruiting
Est. primary completion 2028-10-31 · NCT06140537 · CT.gov ↗
What to watch
November 2028 (2)
Phase 2Heart FailureRecruiting
Est. primary completion 2028-11 · NCT07245069 · CT.gov ↗
What to watch
Phase 4Antipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight GainNot yet recruiting
Est. primary completion 2028-11 · NCT07342764 · CT.gov ↗
What to watch
December 2028 (3)
Phase 2Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2028-12-01 · NCT07741890 · CT.gov ↗
What to watch
Phase 2Type 2 DiabetesNot yet recruiting
Est. primary completion 2028-12-01 · NCT07902726 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2028-12-31 · NCT06642272 · CT.gov ↗
What to watch
2029 (14)
January 2029 (3)
Phase 2Myelodysplastic Syndromes (MDS), AnemiaNot yet recruiting
Est. primary completion 2029-01 · NCT07516847 · CT.gov ↗
What to watch
Phase 2Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2029-01 · NCT06072326 · CT.gov ↗
What to watch
Phase 3Heart FailureRecruiting
Est. primary completion 2029-01-15 · NCT07025629 · CT.gov ↗
What to watch
March 2029 (1)
Phase 4Type 2 DiabetesEnrolling by invitation
Est. primary completion 2029-03-31 · NCT07547878 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Prostate Cancer, Metastatic Prostate CancerRecruiting
Est. primary completion 2029-04-30 · NCT07310433 · CT.gov ↗
What to watch
July 2029 (2)
Phase 2Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2029-07 · NCT07729592 · CT.gov ↗
What to watch
Phase 4Nonobstructive Hypertrophic CardiomyopathyNot yet recruiting
Est. primary completion 2029-07-01 · NCT07897500 · CT.gov ↗
What to watch
August 2029 (4)
Phase 2Aortic StenosisNot yet recruiting
Est. primary completion 2029-08 · NCT07539259 · CT.gov ↗
What to watch
Phase 3Septic ShockNot yet recruiting
Est. primary completion 2029-08 · NCT07488689 · CT.gov ↗
What to watch
Phase 4Kidney Transplant; Complications, Kidney Transplant Failure, Renal FailureActive not recruiting
Est. primary completion 2029-08 · NCT05788276 · CT.gov ↗
What to watch
Phase 4Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2029-08-01 · NCT07254572 · CT.gov ↗
What to watch
September 2029 (1)
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2029-09-01 · NCT07108985 · CT.gov ↗
What to watch
December 2029 (2)
Phase 3Heart FailureRecruiting
Est. primary completion 2029-12-17 · NCT06677060 · CT.gov ↗
What to watch
Phase 3Chronic Kidney DiseaseRecruiting
Est. primary completion 2029-12-18 · NCT06742723 · CT.gov ↗
What to watch
2030 (4)
May 2030 (1)
Phase 3Polycystic Kidney, Autosomal DominantRecruiting
Est. primary completion 2030-05-15 · NCT07280585 · CT.gov ↗
What to watch
July 2030 (1)
Phase 3Chronic Kidney DiseaseRecruiting
Est. primary completion 2030-07-01 · NCT07624305 · CT.gov ↗
What to watch
October 2030 (1)
Phase 4Chronic Hepatitis BRecruiting
Est. primary completion 2030-10-31 · NCT06364930 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Aging, Functional DeclineNot yet recruiting
Est. primary completion 2030-12 · NCT07923630 · CT.gov ↗
What to watch
2031 (1)
March 2031 (1)
Phase 1Pediatric Brain Tumor, Pediatric Solid TumorRecruiting
Est. primary completion 2031-03-31 · NCT05521984 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

7 April 2026ApprovalFDA approves Lupin's generic Dapagliflozin Tablets
US, FDA · Source ↗